Rovi jumps after raising 2026 outlook on strong third-quarter beat

By Reuters News

** Shares in Rovi ROVI.MC jump about 8% after the Spanish pharmaceutical company reported better-than-expected third quarter results and increased its guidance for 2026

** Banco Sabadell broker said third-quarter EBITDA reached €105.4 million ($118.69 million), above €78 million consensus estimates and €83 million estimated by the broker

** Operating revenue for the full year is now expected to grow by a mid-to-high single-digit percentage, higher than the low-to-mid single-digit growth previously forecast, Renta4 broker said

** Renta4 highlighted Rovi's contract manufacturing business (CDMO) strong performance, where third-quarter revenue rose 51% year-on-year, benefiting from higher customer activity and contributions from its agreement with Bristol Myers Squibb

** Shares are on track for their best day since July 2023

($1 = 0.8880 euros)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk